Risdiplam Powder API CAS No:1825352-65-5

Product Introduction

Product Name: Risdiplam Product purity: ≥ 99% (pharmaceutical grade);  ≥ 98% (research level) CAS No: 1825352-65-5 Molecular formula: C22H23N7O Molecular weight: 401.46 Detection method: HPLC Active ingredient: Risdiplam Product Description: White to off white powder Product packaging: 5g, 10g, 100g/bottle Product storage: -25~-15 ℃, dry and avoid light Validity period: 3 years Declaration of Use: This product is intended for industrial use or scientific research only.

Chemical properties of lisipulan

Density: 1.50 ± 0.1g/cm3 (Predicted)

Solubility: Solublin DMSO

Acidity coefficient (pKa): 9.41 ± 0.20 (Predicted)

Form: Solid

Color: Light yellow to yellow

InChI: InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30Chemicalbook)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3

InChIKey: ASKZRYGFUPSJPN-UHFFFAOYSA-N

SMILES: C12C=CC(N3CC4(CC4)NCC3)=CN1C(=O)C=C(C1=NN3C=C(C)N=C3C(C)=C1)N=2

Products  Description  

Overview of Shaanxi Sunrise Risdiplam API

Shaanxi Sunrise focuses on providing high-quality Risdiplam raw materials, with a purity of ≥ 99% as measured by HPLC-UV method, meeting all indicators. The product adopts copper catalytic process to ensure heavy metal residue<1ppm and batch stability of over 99.5%, suitable for large-scale production of oral solutions and tablets.

Raw materials strictly follow cold chain storage and transportation, with stable crystal structure and solubility matching the original research data with bioavailability. Support customized packaging and pre batch supply, helping customers accelerate formulation research and compliance declaration.

Products Function

1. The motor function has been improved or stabilized.

2. Improved survival rate and reduced mortality rate for type 1 critically ill newborns

3. Respiratory and swallowing functions provide protection

4. Enhanced the independence of life

Scope of application

1. Full age coverage

2. Scoliosis/Postoperative Patient Replacement

3. Prenatal intervention

The core human benefits of Liriopide are reflected in

✅ Survival breakthrough: the survival rate of critically ill infants has increased by more than three times;

✅ Functional protection: benefits from multiple systems including movement, breathing, and swallowing, preventing rapid disease progression;

✅ Life empowerment: oral convenience+improved independent mobility, reshaping patient dignity;

✅ Full cycle management: covering the entire disease process from 16 day old infants to adults, and even prenatal interventions.

Products Aplication

1. Production of oral solution

2. Production of tablet compression

3. Research on Prenatal Treatment

Mechanism of Action

The main cause of spinal muscular atrophy (SMA) is the loss or mutation of the SMN1 gene in patients, leading to insufficient expression of systemic functional SMN protein. Risdiplam is a splicing modifier for motor neuron survival gene 2 (SChemicalbookMN2) mRNA, which regulates the splicing of SMN2 gene (SMN1 homologous gene) through dual site specificity. It can promote the inclusion of exon 7 into SMN2 mRNA transcript, thereby increasing the expression level of SMN protein.